EMA calls for sponsor and CRO input on trial data publication plan

By Gareth Macdonald

- Last updated on GMT

EMA, CRO, sponsor, clinical trial data, Doshi, publication

Related tags Clinical trial data Clinical trial

The EMA wants CROs and sponsors to share their thoughts on plans to make data from clinical trials publicly available.

The European Medicines Agency (EMA) has scheduled a meeting on November 22​ and has invited academic and industry stakeholders to help it “define the modalities of proactive access to clinical trial data, in a way that best serves patients and public health in an open and transparent forum.​”

The idea of data publication hit the headlines again in April​ following an article in the PLOS journal in which author Peter Doshi, a postdoctoral fellow in comparative effectiveness research at Johns Hopkins University School of Medicine in the US, ​argued that failing to make all clinical trial data available to the public is hampering independent research.

“Systematic reviews of published randomized clinical trials (RCTs) are considered the gold standard source of synthesized evidence for interventions, but their conclusions are vulnerable to distortion when trial sponsors have strong interests that might benefit from suppressing or promoting selected data.”

Doshi also suggested that – beyond alleged industry suppression of unfavourable clinical trial data – the other part of the problem is that regulators have traditionally treated clinical trials data as confidential.

In a response piece published in the same journal​ the EMA agreed that clinical trial data should not be kept secret for commercial reasons, but did caution that the publication of raw data sets may breach patient confidentiality rules.

The EMA team went on to say that while publication of study data may have public health benefits they also called for the development of “rules of engagement for sharing raw data, with the same standards applying to all clinical trial data on medicines, regardless of the type of sponsor.”

Sponsors and CROs interested in the development of these rules can find out how to register for the EMA meeting here​.

Related topics Clinical Development Phase III-IV

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us